Skip to main content

ChondroGene Raises $5 million in Private Placement

NEW YORK, Aug. 26 (GenomeWeb News) - Toronto-based ChondroGene announced that it has raised US$5 million in a private placement of 5,263,149 common shares priced at US$.95 per share.

 

The firm, which trades on the TSX Venture Exchange, is applying functional genomics to the development of biomarkers for diagnostic and therapeutic purposes.

 

Rodman & Renshaw managed the placement and received $300,000 on the gross proceeds. It also received a warrant entitling the firm to acquire 315,790 shares of ChondroGene at US$.95 per share.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.